Clever Leaves Gains Exclusive License to Cultivate High Performance Cannabis
    Clever Leaves Gains Exclusive License to Cultivate High Performance Cannabis
    PRISM MarketView

    Clever Leaves Gains Exclusive License to Cultivate High Performance Cannabis

    15 February 2024

    New York, February 15, 2024 - PRISM MarketView - PRISM MediaWire - As part of its partnership with award-winning Dutch seed bank, Paradise Seeds, global medicinal cannabis company, Clever Leaves Holdings (Nasdaq: CLVR), will develop and register high performance cannabis cultivars in Colombia, and will have exclusive license to cultivate some of these genetics. Clever Leaves’ share price rose nearly 8% in morning trading on Thursday, following the news.
    Clever Leaves Holdings Inc. - Prism MarketView

    Clever Leaves Holdings Inc. - Prism MarketView

    Clever Leaves is a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids. Its operations in Colombia produce cannabinoid act

    Read More

    Clever Leaves and Paradise Seeds to Develop and Register Genetic Assets in Colombia

    Clever Leaves and Paradise Seeds to Develop and Register Genetic Assets in Colombia

    TOCANCIPÁ, Colombia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a global medicinal cannabis company, announced today that through its partnership with award-winning Dutch seed bank, Paradise Seeds (“Paradise”), to develop and register high performance cannabis cultivars in Colombia, Clever Leaves will have exclusive license to cultivate some of these genetics, while Paradise will make other cultivars available to third

    Read More

    The collaboration is expected to positively impact cannabis patients worldwide, combining Paradise’s experience in breeding and selection of high-quality cannabis strains with Clever Leaves’ expertise in cultivation and production of medicinal cannabis at its facility under Good Manufacturing Practices, which are compliant with standards in the European Union, Australia, Brazil, and Colombia.
    Highlights
    Clever Leaves and Paradise Seeds have begun rigorous selection, phenotyping, and agronomic trials of several Paradise varieties at Clever Leaves’ facility in order to register market-leading cultivars for production and commercialization.
    Paradise will make other cultivars available to third parties for cultivation across Colombia and Latin America.
    Colombian regulations require official registration of all cannabis varieties cultivated in the country, to ensure traceability and transparency in international trade of cannabis flowers and derived products.
    About Clever Leaves Holdings Inc.
    Clever Leaves is a global medicinal cannabis company. Its operations in Colombia produce cannabinoid active pharmaceutical ingredients (API) and finished products in flower and extract form to a growing base of B2B customers around the globe. Clever Leaves aims to disrupt the traditional cannabis production industry by leveraging environmentally sustainable, ESG-friendly, industrial-scale and low-cost production methods, with the world’s most stringent pharmaceutical quality certifications. For more information, please visit https://cleverleaves.com/en/home/

    HOME - Clever Leaves

    WE ARE WE ARE CLEVER LEAVES Your partner for bringing cannabis products to the world An innovative, pharma quality, product portfolio which enables our partners to win in their own markets through efficiency, speed to market, and compliance. Also, we are always looking to improve the well-being of communities where we operate fostering good working

    Read More

    About Paradise Seeds
    Paradise Seeds, established in Amsterdam in 1994, is one of the oldest cannabis seed banks in the world. For three decades, the company has remained at the forefront of innovations in cannabis breeding, winning multiple awards for its high-performance sativa, indica and hybrid strains. Since 2013, Paradise has supplied its genetics under commercial license agreements to medical cannabis companies for large scale cultivation. Medicines produced from its genetics are currently available to patients in Canada, Germany, the U.K. and Australia.
    PRISM MarketView does not provide investment advice.
    Media Contact
    Company Name: Prism MarketView
    Email: info@prismmarketview.com
    Phone: 646-863-6341
    Website: https://prismmarketview.com
    To see this content properly accept cookies.
    PRISM MarketView Social Media
    To see this content properly accept cookies.
    PRISM MediaWire - Blog
    To see this content properly accept cookies.
    PRISM MediaWire - Social Media (X)
    To see this content properly accept cookies.
    To see this content properly accept cookies.
    To see this content properly accept cookies.
    Related Stories
    PRISM MarketView
    PRISM NextGen Tech Stocks Soundhound AI (SOUN) and Recursion Pharmaceuticals (RXRX) See Share Prices Soar From Nvidia Disclosure

    New York, February 15, 2024 - PRISM MarketView - PRISM MediaWire - Today the megacap AI chipmaker Nvidia (NVDA) disclosed its stake in some smaller AI firms that has boosted shares for those associated with the disclosure.

    15 February 2024

    PRISM MarketView
    Greenwich LifeSciences Provides Update on Phase III Clinical Trial for Breast Cancer Immunotherapy; Shares Surge

    New York, February 15, 2024 - PRISM MarketView - PRISM MediaWire - Greenwich LifeSciences, Inc. (Nasdaq: GLSI), a clinical-stage biopharmaceutical company, provided an update on its Phase III clinical trial, Flamingo-01, focusing on GLSI-100, an immunotherapy aimed at pr...

    15 February 2024

    PRISM MarketView
    Atara Biotherapeutics Files IND to Advance Lupus Treatment

    New York, February 15, 2024 - PRISM MarketView - PRISM MediaWire - Atara Biotherapeutics (Nasdaq: ATRA) has submitted an Investigational New Drug (IND) application to the FDA for the use of ATA3219 as a monotherapy for the treatment of systemic lupus erythematosus(SLE) w...

    15 February 2024

    PRISM MarketView
    PRISM MedDevice Mover: Sensus HealthCare

    New York, February 16, 2024 - PRISM MarketView - PRISM MediaWire - Sensus Healthcare, Inc. (Nasdaq: SRTS) is at the forefront of superficial radiation therapy devices, with a diverse product range aimed at treating non-melanoma skin cancers and various other cancers. The...

    16 February 2024

    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.